Vical Incorporated (VICL) Reports Second Quarter 2013 Financial Results, Projects Phase 3 Data Release in August and Establishes Quiet Period
8/1/2013 9:48:50 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2013. Revenues were $1.5 million for the second quarter of 2013 compared with $1.6 million for the second quarter of 2012, reflecting ongoing reimbursements from Astellas Pharma Inc. for expenses related to the development of ASP0113 (TransVax™), Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. The net loss was $9.9 million, or $0.11 per share, for the second quarter of 2013, compared with $7.9 million, or $0.09 per share, for the second quarter of 2012.
Help employers find you! Check out all the jobs and post your resume.
comments powered by